Detailed curriculum vitae of HER2-targeted therapy

Xiao-Nan Zhang; Ya Gao; Xi-Ya Zhang; Ning-Jie Guo; Wen-Qing Hou; Shu-Wu Wang; Yi-Chao Zheng; Ning Wang; Hong-Min Liu; Bo Wang

doi:10.1016/j.pharmthera.2023.108417

Detailed curriculum vitae of HER2-targeted therapy

Pharmacol Ther. 2023 May:245:108417. doi: 10.1016/j.pharmthera.2023.108417. Epub 2023 Apr 17.

Authors

Affiliations

¹ State Key Laboratory of Esophageal Cancer Prevention and Treatment, Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education of China, Key Laboratory of Henan Province for Drug Quality and Evaluation, Institute of Drug Discovery and Development, Zhengzhou University, Zhengzhou, China.
² The School of Chinese Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China.
³ State Key Laboratory of Esophageal Cancer Prevention and Treatment, Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education of China, Key Laboratory of Henan Province for Drug Quality and Evaluation, Institute of Drug Discovery and Development, Zhengzhou University, Zhengzhou, China. Electronic address: liuhm@zzu.edu.cn.
⁴ The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, China; State Key Laboratory of Esophageal Cancer Prevention and Treatment, Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education of China, Key Laboratory of Henan Province for Drug Quality and Evaluation, Institute of Drug Discovery and Development, Zhengzhou University, Zhengzhou, China. Electronic address: wangbo0601@zzu.edu.cn.

PMID: 37075933
DOI: 10.1016/j.pharmthera.2023.108417

Abstract

With the booming development of precision medicine, molecular targeted therapy has been widely used in clinical oncology treatment due to a smaller number of side effects and its superior accuracy compared to that of traditional strategies. Among them, human epidermal growth factor receptor 2 (HER2)-targeted therapy has attracted considerable attention and has been used in the clinical treatment of breast and gastric cancer. Despite excellent clinical effects, HER2-targeted therapy remains in its infancy due to its resulting inherent and acquired resistance. Here, a comprehensive overview of HER2 in numerous cancers is presented, including its biological role, involved signaling pathways, and the status of HER2-targeted therapy.

Keywords: Cancer; HER2; Inhibitor; Resistance.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Breast Neoplasms* / drug therapy
Drug Resistance, Neoplasm*
Female
Humans
Molecular Targeted Therapy / methods
Signal Transduction

Substances

ERBB2 protein, human